This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Orforglipron, an oral non-peptide GLP-1 agonist, improved beta cell function markers by up to 132% and insulin sensitivity in type 2 diabetes patients, with effects exceeding those of injectable dulaglutide.
Why it matters
Orforglipron could make GLP-1 therapy accessible as a daily pill rather than an injection. It not only controls blood sugar but appears to improve the underlying pancreatic and metabolic dysfunction driving type 2 diabetes.
The numbers in context
378 participants. HOMA-B increased up to 123% (C-peptide) and 132% (insulin) at doses of 12 mg and higher by week 4. HOMA-IR decreased up to 16-23% by week 26. Greater HOMA-B increases than dulaglutide 1.5 mg. Proinsulin/insulin ratio improved. 26-week study.
How the study worked
Exploratory analysis of a 26-week phase 2 RCT. Orforglipron 3, 12, 24, 36, or 45 mg daily vs. dulaglutide 1.5 mg weekly vs. placebo. Beta cell function and insulin sensitivity biomarkers assessed.
Who was studied
Adults with inadequately controlled type 2 diabetes
What this study cannot tell us
Exploratory post-hoc analysis. Phase 2, not powered for beta cell endpoints. 26-week duration. Cannot determine if beta cell improvements are sustained long-term. Dulaglutide comparison at only one dose.
Read the original research
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
Diabetes, obesity & metabolism, 27(11), 6314-6322
Citation
Rosenstock, Julio; Robins, Deborah A; Duffin, Kevin L; Wilson, Jonathan M; Lin, Yanzhu; Banerjee, Hiya; Eyde, Sarah; Kazda, Christof; Konig, Manige; Mather, Kieren J. (2025). Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.. Diabetes, obesity & metabolism, 27(11), 6314-6322. https://doi.org/10.1111/dom.70022